Reports and Findings
Research
Comparison of experiences in two birth cohorts comprising young families with children under four years during the initial Covid-19 lockdown in Australia and the UK: A qualitative studyThis study aims to understand the experience and impact of the initial COVID-19 lock-down in young families with children aged below 4 years. Free text questions were administered to participants in the ORIGINS (Australia) and Born in Bradford (UK) cohort studies to collect qualitative information on worries, concerns and enjoyable experiences during the pandemic.
Research
UV light and COVID-19Investigator: Nisali Gamage Project description We critically review new studies which are emerging that report findings related to the effects of UV light and sun exposure on COVID-19. We have published a review of studies published in 2020.
Research
Implementation of on-line training modules in paediatric Aboriginal lung healthAndré Schultz AS MBChB, PhD, FRACP Program Head, Respiratory Health RFA Program Head, Respiratory Health RFA Prof André Schultz is the Program Head of Respiratory Health and Head of the BREATH Team at Telethon Kids Institute. He is passionate
Research
Using syringe infusion pumps Springfusors for the administration of intravenous antibiotics for children with CF at PCH (SIPS-CF)André Schultz AS MBChB, PhD, FRACP Program Head, Respiratory Health RFA Program Head, Respiratory Health RFA Prof André Schultz is the Program Head of Respiratory Health and Head of the BREATH Team at Telethon Kids Institute. He is passionate
Research
Adaption and implementation of Aboriginal child lung health tools for northern Western AustraliaAndré Schultz AS MBChB, PhD, FRACP Program Head, Respiratory Health RFA Program Head, Respiratory Health RFA Prof André Schultz is the Program Head of Respiratory Health and Head of the BREATH Team at Telethon Kids Institute. He is passionate
Research
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine with Aluminium in Healthy Third-trimester Pregnant Women; and SafetyElke Jennifer Peter Seppanen Kent Richmond ES J PC BSc PhD RN MBBS MRCP(UK) FRACP Program Manager, Bacterial Respiratory Infectious Disease Group Clinical Research Manager Head, Vaccine Trials Group elke.seppanen@telethonkids.org.au Jennifer.Kent@
Research
Sore Throat Melbourne and Perth Study: The Australian Strep A Vaccine Initiative (ASAVI) Urban Pharyngitis Surveillance Study (STAMPS)Jonathan Peter Carapetis AM Richmond JR PC AM MBBS FRACP FAFPHM PhD FAHMS MBBS MRCP(UK) FRACP Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH Head, Vaccine Trials Group 08 6319 1000 contact@telethonkids.org.au Institute
Research
The relationship between meal carbohydrate quantity and the insulin to carbohydrate ratio required to maintain glycaemia is non-linear in young people with type 1 diabetes: A randomized crossover trialTo determine if the relationship between meal carbohydrate quantity and the insulin to carbohydrate ratio (ICR) required to maintain glycaemia is linear in people with type 1 diabetes.
Research
COVALIA (COVid vaccine trial for austrALIA): A phase I, double-blind, dose-ranging, randomised, placebo-controlled trial to study the safety and immunogenicity of a DNA-based vaccine against COVID-19 (COVIGEN) in healthy participants aged 18 to 75 years oPeter Richmond PC MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group which sits in the Wesfarmers Centre of Vaccines and Infectious Diseases. Professor Richmond is a
Research
A phase IIIB, randomized, controlled, observer-blind study to evaluate safety and immunogenicity of GSK’s meningococcal ABCWY vaccine when administered in healthy adolescents and adults, previously primed with meningococcal ACWY vaccine (BOOST)Investigator: Peter Richmond Project description GSK is conducting a research study to evaluate its investigational, pentavalentmeningococcal vaccine, MenABCWY, which is based upon two licensed GSKmeningococcal vaccines, Menveo (MenACWY vaccine) and